Clinical trials: Autoimmune Bullous Disease
Pemphigus
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus is a severe autoimmune blistering disease mediated by circulating antibodies against certain proteins important for maintaining skin integrity.
- Trial name
- NCT00656656
- Testing
- Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- University of Luebeck
Pemphigoid, Bullous
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
This is an open-label, proof-of-concept, single group study in adult participants with newly diagnosed, moderate to extensive BP.
- Trial name
- NCT02226146
- Testing
- Bertilimumab
- Where
- 8 sites in United States, Israel
- Volunteers
- 11 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Bullous Pemphigoid
Rituximab in the Treatment of Patients With Bullous Pemphigoid
This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.
- Trial name
- NCT00286325
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Bullous Pemphigoid
A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
The purpose of this study is to evaluate the safety of efgartigimod PH20 SC over a longer period of time in adult participants with moderate-to-severe bullous pemphigoid (BP) who have completed ARGX-113-2009 study.
- Trial name
- BALLAD+ (NCT05681481)
- Testing
- efgartigimod PH20 SC, Prednisone
- Where
- 40 sites in United States, Australia and 15 more
- Volunteers
- 64 people
- Sponsor
- argenx
Pemphigoid, Bullous
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).
- Trial name
- NCT04499235
- Testing
- Mometasone furoate, AKST4290
- Where
- 8 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Alkahest, Inc.
Bullous Pemphigoid
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment
To evaluate the safety and efficacy of QGE031 versus placebo in patients with bullous pemphigoid. Efficacy will be assessed as a reduction of disease activity.
- Trial name
- NCT01688882
- Testing
- QGE031
- Where
- 9 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Bullous Pemphigoid, Pemphigoid
Ixekizumab in the Treatment of Bullous Pemphigoid
Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin…
- Trial name
- NCT03099538
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Bullous Pemphigoid
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of patients symptomatic Bullous Pemphigoid (BP).
- Trial name
- FJORD (NCT04612790)
- Testing
- Benralizumab
- Where
- 39 sites in United States, Australia and 9 more
- Volunteers
- 67 people
- Sponsor
- AstraZeneca
Bullous Pemphigoid
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity…
- Trial name
- BALLAD (NCT05267600)
- Testing
- efgartigimod PH20 SC, Prednisone
- Where
- 129 sites in United States, Australia and 19 more
- Volunteers
- 98 people
- Sponsor
- argenx
Ocular Cicatricial Pemphigoid
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness.
- Trial name
- NCT00584935
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
Bullous Pemphigoid
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody".
- Trial name
- LIBERTY-BP (NCT04206553)
- Testing
- dupilumab, Oral corticosteroids (OCS)
- Where
- 53 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Regeneron Pharmaceuticals
Bullous Pemphigoid
Efficacy and Safety of Omalizumab in Bullous Pemphigoid
The primary objective is to test the safety and efficacy of Xolair in the treatment of the autoimmune blistering disease, bullous pemphigoid (BP). This is a pilot, open label case-control study.
- Trial name
- NCT00472030
- Testing
- Omalizumab, prednisone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Iowa